Literature DB >> 10761978

Calcium antagonist isradipine reduces metabolic alterations in acute cerebral ischemia in spontaneously hypertensive rats.

S Ibayashi1, T Nagao, T Kitazono, H Ooboshi, J Kitayama, S Sadoshima, M Fujishima.   

Abstract

The present study was designed to examine the effect of a calcium antagonist isradipine (PN200-110: PN) on local cerebral blood flow and brain tissue metabolism after 1-hour supratentorial ischemia induced by bilateral carotid artery ligation (BCL) in spontaneously hypertensive rats (SHR). PN, dissolved in ethanol plus polyethylene glycol 400, diluted with saline to make the final concentration of 0.25mg/ml and 2.5mg/ml, was administered subcutaneously either 30 min prior to BCL or just after the induction of incomplete cerebral ischemia (n = 7 in each group). Vehicle injection was served as a control group (n = 7). Cerebral blood flow in the parietal cortex (CBF) and the cerebellar cortex (CeBF) was measured by hydrogen clearance technique, and the supra- and infratentorial metabolites of the brain frozen in situ were determined by the enzymatic method. Blood pressure was lowered, but CBF was increased by PN administration in pre-BCL treatment study. After 1 hour of BCL, CBF decreased to around 10% or less of the resting value, being insignificant among the groups. Brain adenosine triphosphate was better preserved in PN-administered groups. The increase in lactate level tended to reduce dose dependently by PN treatment. PN also reduced the metabolic alterations in brain tissue with significance, even when administered just after the induction of forebrain ischemia. It is considered that pre- as well as post-BCL administration of PN is beneficial to attenuate the metabolic alterations in incomplete forebrain ischemia in SHR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761978     DOI: 10.1023/a:1007536919827

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  17 in total

1.  Dihydropyridine calcium antagonists reduce the consumption of high-energy phosphates in the rat brain. A study using combined 31P/1H magnetic resonance spectroscopy and 31P saturation transfer.

Authors:  M Rudin; A Sauter
Journal:  J Pharmacol Exp Ther       Date:  1989-11       Impact factor: 4.030

2.  An ultrastructural study of developing cerebral infarction following bilateral carotid artery occlusion in spontaneously hypertensive rats.

Authors:  J Ogata; M Fujishima; K Tamaki; Y Nakatomi; T Omae
Journal:  Acta Neuropathol       Date:  1977-10-10       Impact factor: 17.088

3.  Prevention of ischemic and postischemic brain edema by a novel calcium antagonist (PN200-110).

Authors:  K Abe; K Kogure; T Watanabe
Journal:  J Cereb Blood Flow Metab       Date:  1988-06       Impact factor: 6.200

4.  Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats.

Authors:  C A Campbell; K B Mackay; S Patel; P D King; J L Stretton; S J Hadingham; T C Hamilton
Journal:  Exp Neurol       Date:  1997-11       Impact factor: 5.330

5.  Failure of flunarizine to improve cerebral blood flow or neurologic recovery in a canine model of complete cerebral ischemia.

Authors:  L A Newberg; P A Steen; J H Milde; J D Michenfelder
Journal:  Stroke       Date:  1984 Jul-Aug       Impact factor: 7.914

6.  Isradipine attenuates the ischemia-induced release of dopamine in the striatum of the rat.

Authors:  H Ooboshi; S Sadoshima; S Ibayashi; H Yao; H Uchimura; M Fujishima
Journal:  Eur J Pharmacol       Date:  1993-03-16       Impact factor: 4.432

7.  Isradipine, a calcium channel blocker, attenuates the ischemia-induced release of dopamine but not glutamate in rats.

Authors:  H Nakane; H Ooboshi; S Ibayashi; H Yao; S Sadoshima; M Fujishima
Journal:  Neurosci Lett       Date:  1995-03-31       Impact factor: 3.046

8.  Alteration of voltage-dependent calcium channels in canine brain during global ischemia and reperfusion.

Authors:  P J Hoehner; T J Blanck; R Roy; R E Rosenthal; G Fiskum
Journal:  J Cereb Blood Flow Metab       Date:  1992-05       Impact factor: 6.200

9.  Cerebrovascular, biochemical, and cytoprotective effects of isradipine in laboratory animals.

Authors:  A Sauter; M Rudin; K H Wiederhold; R P Hof
Journal:  Am J Med       Date:  1989-04-17       Impact factor: 4.965

10.  PN 200-110, a new calcium antagonist: electrophysiological, inotropic, and chronotropic effects on guinea pig myocardial tissue and effects on contraction and calcium uptake of rabbit aorta.

Authors:  R P Hof; G Scholtysik; R Loutzenhiser; H J Vuorela; P Neumann
Journal:  J Cardiovasc Pharmacol       Date:  1984 May-Jun       Impact factor: 3.105

View more
  1 in total

1.  Preconditioning with a novel metallopharmaceutical NO donor in anesthetized rats subjected to brain ischemia/reperfusion.

Authors:  Marcio Wilker Soares Campelo; Reinaldo Barreto Oriá; Luiz Gonzaga de França Lopes; Gerly Anne de Castro Brito; Armenio Aguiar dos Santos; Raquel Cavalcante de Vasconcelos; Francisco Ordelei Nascimento da Silva; Beatrice Nuto Nobrega; Moisés Tolentino Bento-Silva; Paulo Roberto Leitão de Vasconcelos
Journal:  Neurochem Res       Date:  2011-12-10       Impact factor: 3.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.